Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient
This is the first report of one lung adenocarcinoma patient with a novel ELMOD3-ALK, EML4-ALK double-ALK fusion. This double-ALK fusion variant is sensitive to alectinib, suggesting patients with an ELMOD3-ALK, EML4-ALK double-ALK fusion could achieve clinical survival benefit from alectinib.
Authors
- Peng Lei (ORCID: https://orcid.org/0000-0001-5652-1962)
- Yinyin Xue
- Kaili Huang (ORCID: https://orcid.org/0009-0006-7246-6952)
- Qinghua Zhou
- Qiang Wu (ORCID: https://orcid.org/0000-0002-5425-815X)
- Wen Li (ORCID: https://orcid.org/0000-0002-1747-9594)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.3389/fphar.2025.1515826
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Sichuan University
- Natural Science Foundation of Sichuan Province
- West China Hospital, Sichuan University